Does the media favor RYTM or ABCL?

In the previous week, AbCellera Biologics had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 3 mentions for AbCellera Biologics and 1 mentions for Rhythm Pharmaceuticals. AbCellera Biologics' average media sentiment score of 0.64 beat Rhythm Pharmaceuticals' score of 0.60 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ABCL or MIRM?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.64 beat Mirum Pharmaceuticals' score of 0.63 indicating that AbCellera Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TGTX or ABCL?

In the previous week, TG Therapeutics had 11 more articles in the media than AbCellera Biologics. MarketBeat recorded 14 mentions for TG Therapeutics and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.64 beat TG Therapeutics' score of 0.54 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CNTA or ABCL?

In the previous week, AbCellera Biologics had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 3 mentions for AbCellera Biologics and 2 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.77 beat AbCellera Biologics' score of 0.64 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SRRK or ABCL?

In the previous week, Scholar Rock and Scholar Rock both had 3 articles in the media. AbCellera Biologics' average media sentiment score of 0.64 beat Scholar Rock's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AbCellera Biologics (ABCL) Competitors

$5.62 -0.75 (-11.77%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$5.78 +0.16 (+2.90%)

As of 06/5/2026 07:58 PM Eastern

Compare

ABCL vs. RYTM, MIRM, TGTX, CNTA, and SRRK

Should you buy AbCellera Biologics stock or one of its competitors? MarketBeat compares AbCellera Biologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AbCellera Biologics include Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), TG Therapeutics (TGTX), Centessa Pharmaceuticals (CNTA), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, AbCellera Biologics had 2 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 3 mentions for AbCellera Biologics and 1 mentions for Rhythm Pharmaceuticals. AbCellera Biologics' average media sentiment score of 0.64 beat Rhythm Pharmaceuticals' score of 0.60 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.4% of AbCellera Biologics shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AbCellera Biologics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	31.20	-$196.54M	-$3.13	N/A
AbCellera Biologics	$75.13M	22.84	-$146.41M	-$0.48	N/A

Rhythm Pharmaceuticals presently has a consensus price target of $131.81, suggesting a potential upside of 52.56%. AbCellera Biologics has a consensus price target of $7.80, suggesting a potential upside of 38.79%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rhythm Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Rhythm Pharmaceuticals has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

Summary

AbCellera Biologics beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

AbCellera Biologics (NASDAQ:ABCL) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

AbCellera Biologics presently has a consensus price target of $7.80, indicating a potential upside of 38.79%. Mirum Pharmaceuticals has a consensus price target of $137.64, indicating a potential upside of 47.24%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has a net margin of -140.24% compared to AbCellera Biologics' net margin of -181.75%. Mirum Pharmaceuticals' return on equity of -11.28% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-181.75%	-14.86%	-10.62%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for Mirum Pharmaceuticals and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.64 beat Mirum Pharmaceuticals' score of 0.63 indicating that AbCellera Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	22.84	-$146.41M	-$0.48	N/A
Mirum Pharmaceuticals	$521.31M	10.93	-$23.36M	-$13.61	N/A

61.4% of AbCellera Biologics shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Mirum Pharmaceuticals beats AbCellera Biologics on 10 of the 16 factors compared between the two stocks.

How does AbCellera Biologics compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

TG Therapeutics currently has a consensus target price of $52.50, indicating a potential upside of 30.73%. AbCellera Biologics has a consensus target price of $7.80, indicating a potential upside of 38.79%. Given AbCellera Biologics' higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

TG Therapeutics has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	9.98	$447.18M	$2.86	14.04
AbCellera Biologics	$75.13M	22.84	-$146.41M	-$0.48	N/A

TG Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to AbCellera Biologics' net margin of -181.75%. TG Therapeutics' return on equity of 88.73% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

In the previous week, TG Therapeutics had 11 more articles in the media than AbCellera Biologics. MarketBeat recorded 14 mentions for TG Therapeutics and 3 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 0.64 beat TG Therapeutics' score of 0.54 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

TG Therapeutics beats AbCellera Biologics on 10 of the 15 factors compared between the two stocks.

How does AbCellera Biologics compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Centessa Pharmaceuticals currently has a consensus price target of $41.33, indicating a potential upside of 4.32%. AbCellera Biologics has a consensus price target of $7.80, indicating a potential upside of 38.79%. Given AbCellera Biologics' stronger consensus rating and higher probable upside, analysts plainly believe AbCellera Biologics is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, AbCellera Biologics had 1 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 3 mentions for AbCellera Biologics and 2 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.77 beat AbCellera Biologics' score of 0.64 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Centessa Pharmaceuticals has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

AbCellera Biologics has higher revenue and earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	394.17	-$197.53M	-$1.79	N/A
AbCellera Biologics	$75.13M	22.84	-$146.41M	-$0.48	N/A

Centessa Pharmaceuticals has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

Summary

AbCellera Biologics beats Centessa Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does AbCellera Biologics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are held by institutional investors. 13.3% of Scholar Rock shares are held by insiders. Comparatively, 28.4% of AbCellera Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Scholar Rock presently has a consensus price target of $56.00, suggesting a potential upside of 26.41%. AbCellera Biologics has a consensus price target of $7.80, suggesting a potential upside of 38.79%. Given AbCellera Biologics' higher probable upside, analysts clearly believe AbCellera Biologics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Scholar Rock has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

In the previous week, Scholar Rock and Scholar Rock both had 3 articles in the media. AbCellera Biologics' average media sentiment score of 0.64 beat Scholar Rock's score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AbCellera Biologics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
AbCellera Biologics	$75.13M	22.84	-$146.41M	-$0.48	N/A

Scholar Rock has a net margin of 0.00% compared to AbCellera Biologics' net margin of -181.75%. AbCellera Biologics' return on equity of -14.86% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
AbCellera Biologics	-181.75%	-14.86%	-10.62%

Summary

AbCellera Biologics beats Scholar Rock on 10 of the 15 factors compared between the two stocks.

Get AbCellera Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABCL vs. The Competition

Export

Metric	AbCellera Biologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.35B	$6.47B	$12.42B
Dividend Yield	N/A	2.33%	2.68%	5.34%
P/E Ratio	-11.71	18.85	23.79	23.63
Price / Sales	22.84	307.82	543.15	124.82
Price / Cash	N/A	114.83	42.35	57.17
Price / Book	1.74	6.51	9.73	6.35
Net Income	-$146.41M	$24.15M	$3.57B	$337.59M
7 Day Performance	-8.91%	-6.96%	-1.25%	-2.51%
1 Month Performance	11.51%	-4.27%	0.83%	-0.68%
1 Year Performance	130.33%	36.81%	24.11%	25.37%

AbCellera Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABCL AbCellera Biologics	2.7054 of 5 stars	$5.62 -11.8%	$7.80 +38.8%	+137.1%	$1.95B	$75.13M	N/A	500	News Coverage Gap Down
RYTM Rhythm Pharmaceuticals	2.6487 of 5 stars	$87.84 -2.6%	$131.81 +50.1%	+30.6%	$6.02B	$189.76M	N/A	140	Analyst Forecast
MIRM Mirum Pharmaceuticals	3.5926 of 5 stars	$98.62 -2.0%	$137.08 +39.0%	+109.4%	$6.01B	$569.61M	N/A	140	Analyst Forecast Insider Trade
TGTX TG Therapeutics	3.6528 of 5 stars	$38.87 -0.9%	$52.50 +35.1%	+2.2%	$5.95B	$616.29M	13.59	290
CNTA Centessa Pharmaceuticals	2.1449 of 5 stars	$39.75 -0.2%	$40.70 +2.4%	+234.1%	$5.93B	N/A	N/A	200	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABCL) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbCellera Biologics (ABCL) Competitors

ABCL vs. RYTM, MIRM, TGTX, CNTA, and SRRK

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Summary

How does AbCellera Biologics compare to TG Therapeutics?

Summary

How does AbCellera Biologics compare to Centessa Pharmaceuticals?

Summary

How does AbCellera Biologics compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AbCellera Biologics (ABCL) Competitors

ABCL vs. RYTM, MIRM, TGTX, CNTA, and SRRK

How does AbCellera Biologics compare to Rhythm Pharmaceuticals?

Does the media favor RYTM or ABCL?

Do institutionals and insiders believe in RYTM or ABCL?

Which has higher valuation and earnings, RYTM or ABCL?

Do analysts rate RYTM or ABCL?

Which has more volatility and risk, RYTM or ABCL?

Is RYTM or ABCL more profitable?

Summary

How does AbCellera Biologics compare to Mirum Pharmaceuticals?

Do analysts recommend ABCL or MIRM?

Is ABCL or MIRM more profitable?

Does the media prefer ABCL or MIRM?

Which has more risk and volatility, ABCL or MIRM?

Which has higher earnings and valuation, ABCL or MIRM?

Do insiders & institutionals have more ownership in ABCL or MIRM?

Summary

How does AbCellera Biologics compare to TG Therapeutics?

Do analysts recommend TGTX or ABCL?

Which has preferable valuation and earnings, TGTX or ABCL?

Which has more volatility and risk, TGTX or ABCL?

Is TGTX or ABCL more profitable?

Does the media prefer TGTX or ABCL?

Do institutionals and insiders have more ownership in TGTX or ABCL?

Summary

How does AbCellera Biologics compare to Centessa Pharmaceuticals?

Do analysts rate CNTA or ABCL?

Do institutionals & insiders have more ownership in CNTA or ABCL?

Does the media favor CNTA or ABCL?

Is CNTA or ABCL more profitable?

Which has better earnings and valuation, CNTA or ABCL?

Which has more risk and volatility, CNTA or ABCL?

Summary

How does AbCellera Biologics compare to Scholar Rock?

Do insiders & institutionals hold more shares of SRRK or ABCL?

Do analysts prefer SRRK or ABCL?

Which has more risk & volatility, SRRK or ABCL?

Does the media prefer SRRK or ABCL?

Which has stronger earnings & valuation, SRRK or ABCL?

Is SRRK or ABCL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL vs. The Competition

AbCellera Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools